F. Innocenti, R. Danesi, D. Paolo, A. Agen, C. Nardini et al., Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice, Drug Metab Dispos, vol.23, pp.713-720, 1995.

T. Voloshin, E. Voest, and Y. Shaked, The host immunological response to cancer therapy: An emerging concept in tumor biology, Experimental Cell Research, vol.319, issue.11, pp.1687-95, 2013.
DOI : 10.1016/j.yexcr.2013.03.007

Y. Shaked, Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects, Nature Reviews Clinical Oncology, vol.60, issue.10, pp.611-637, 2016.
DOI : 10.1073/pnas.0911378107

Y. Shaked, E. Henke, J. Roodhart, P. Mancuso, M. Langenberg et al., Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents, Cancer Cell, vol.14, issue.3, pp.263-73, 2008.
DOI : 10.1016/j.ccr.2008.08.001
URL : https://doi.org/10.1016/j.ccr.2008.08.001

J. Roodhart, L. Daenen, E. Stigter, H. Prins, J. Gerrits et al., Mesenchymal Stem Cells Induce Resistance to Chemotherapy through the Release of Platinum-Induced Fatty Acids, Cancer Cell, vol.20, issue.3, pp.370-83, 2011.
DOI : 10.1016/j.ccr.2011.08.010

E. Hasnis, D. Alishekevitz, S. Gingis-veltski, R. Bril, E. Fremder et al., Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy, Neoplasia, vol.16, issue.6, pp.501-511, 2014.
DOI : 10.1016/j.neo.2014.05.011
URL : https://doi.org/10.1016/j.neo.2014.05.011

O. Beyar-katz, K. Magidey, N. Ben-tsedek, D. Alishekevitz, M. Timaner et al., Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy, The Journal of Pathology, vol.3, issue.131, pp.262-73, 2016.
DOI : 10.1371/journal.pone.0003287

S. Gingis-velitski, D. Loven, L. Benayoun, M. Munster, R. Bril et al., Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice, Cancer Research, vol.71, issue.22, pp.6986-96, 2011.
DOI : 10.1158/0008-5472.CAN-11-0629
URL : http://cancerres.aacrjournals.org/content/canres/71/22/6986.full.pdf

Y. Shaked, A. Ciarrocchi, M. Franco, C. Lee, S. Man et al., Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors, Science, vol.313, issue.5794, pp.1785-1792, 2006.
DOI : 10.1126/science.1127592

J. Kim and I. Tannock, Repopulation of cancer cells during therapy: an important cause of treatment failure, Nature Reviews Cancer, vol.65, issue.7, pp.516-541, 2005.
DOI : 10.1016/S0090-4295(03)00776-3

I. Tannock, Resistance through repopulation, Nature, vol.36, issue.7533, pp.152-155, 2015.
DOI : 10.1016/j.clinthera.2014.06.015

G. Klement, S. Baruchel, J. Rak, S. Man, K. Clark et al., Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity, Journal of Clinical Investigation, vol.105, issue.8, pp.15-24, 2000.
DOI : 10.1172/JCI8829
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC517491/pdf

D. Hanahan, G. Bergers, and E. Bergsland, Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice, Journal of Clinical Investigation, vol.105, issue.8, pp.1045-1052, 2000.
DOI : 10.1172/JCI9872

Y. Shaked, U. Emmengger, S. Man, D. Cervi, F. Bertolini et al., Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity, Blood, vol.106, issue.9, pp.3058-61, 2005.
DOI : 10.1182/blood-2005-04-1422

Y. Shaked, E. Pham, S. Hariharan, K. Magidey, O. Beyar-katz et al., Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy, Cancer Research, vol.76, issue.20, pp.5983-93, 2016.
DOI : 10.1158/0008-5472.CAN-16-0136

D. Barbolosi, J. Ciccolini, B. Lacarelle, F. Barlesi, and N. Andre, Computational oncology ??? mathematical modelling of drug regimens for precision medicine, Nature Reviews Clinical Oncology, vol.32, issue.4, pp.242-54, 2016.
DOI : 10.1007/s00280-014-2546-1

S. Benzekry, C. Lamont, D. Barbolosi, L. Hlatky, and P. Hahnfeldt, Mathematical modeling of tumor-tumor distant interactions supports a systemic control of tumor growth, Cancer Res, vol.77, pp.5183-5193, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01566947

S. Benzekry, C. Lamont, A. Beheshti, A. Tracz, J. Ebos et al., Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth, PLoS Computational Biology, vol.90, issue.8, p.1003800, 2014.
DOI : 10.1371/journal.pcbi.1003800.s010

S. Benzekry, A. Tracz, M. Mastri, R. Corbelli, D. Barbolosi et al., Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach, Cancer Research, vol.76, issue.3, pp.535-582, 2016.
DOI : 10.1158/0008-5472.CAN-15-1389
URL : https://hal.archives-ouvertes.fr/hal-01222046

J. Ciccolini, D. Barbolosi, C. Meille, A. Lombard, C. Serdjebi et al., Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy, Cancer Research, vol.77, issue.17, pp.4723-4733, 2017.
DOI : 10.1158/0008-5472.CAN-16-3130

S. Benzekry, E. Pasquier, D. Barbolosi, B. Lacarelle, F. Barlesi et al., Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine, Seminars in Cancer Biology, vol.35, pp.53-61, 2015.
DOI : 10.1016/j.semcancer.2015.09.002
URL : https://hal.archives-ouvertes.fr/hal-01195547

P. Friedl and K. Wolf, Tumour-cell invasion and migration: diversity and escape mechanisms, Nature Reviews Cancer, vol.3, issue.5, pp.362-74, 2003.
DOI : 10.1038/nrc1075

C. Holohan, V. Schaeybroeck, S. Longley, D. Johnston, and P. , Cancer drug resistance: an evolving paradigm, Nature Reviews Cancer, vol.14, issue.10, pp.714-740, 2013.
DOI : 10.1093/neuonc/nos158

O. Katz and Y. Shaked, Host effects contributing to cancer therapy resistance, Drug Resistance Updates, vol.19, pp.33-42, 2015.
DOI : 10.1016/j.drup.2014.12.002

T. Shree, O. Olson, B. Elie, J. Kester, A. Garfall et al., Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer, Genes & Development, vol.25, issue.23, pp.2465-79, 2011.
DOI : 10.1101/gad.180331.111
URL : http://genesdev.cshlp.org/content/25/23/2465.full.pdf

T. Chan, C. Hsu, V. Pai, W. Liao, S. Huang et al., Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells, The Journal of Experimental Medicine, vol.28, issue.13, pp.2967-88, 2016.
DOI : 10.1158/2159-8290.CD-14-1101

Y. Shaked and R. Kerbel, Antiangiogenic Strategies on Defense: On the Possibility of Blocking Rebounds by the Tumor Vasculature after Chemotherapy, Cancer Research, vol.67, issue.15, pp.7055-7063, 2007.
DOI : 10.1158/0008-5472.CAN-07-0905

F. Bertolini, S. Paul, P. Mancuso, S. Monestiroli, A. Gobbi et al., Maximum tolerable dose and lowdose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells, Cancer Res, vol.63, pp.4342-4348, 2003.

E. Pasquier, M. Kavallaris, and N. Andre, Metronomic chemotherapy: new rationale for new directions, Nature Reviews Clinical Oncology, vol.1805, issue.8, pp.455-65, 2010.
DOI : 10.1016/0002-9394(77)90132-5

I. Kareva, A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells, International Journal of Molecular Sciences, vol.60, issue.10, 2017.
DOI : 10.1146/annurev.immunol.26.021607.090331

K. Parra, P. Valenzuela, N. Lerma, A. Gallegos, L. Reza et al., Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth, British Journal of Cancer, vol.58, issue.3, pp.324-358, 2017.
DOI : 10.1038/nature13954

D. Loven, E. Hasnis, F. Bertolini, and Y. Shaked, Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer, Drug Discovery Today, vol.18, issue.3-4, pp.193-201, 2013.
DOI : 10.1016/j.drudis.2012.07.015

J. Pasquier, H. Thawadi, P. Ghiabi, N. Abu-kaoud, M. Maleki et al., Microparticles mediated cross-talk between tumoral and endothelial cells promote the constitution of a pro-metastatic vascular niche through Arf6 up regulation, Cancer Microenvironment, vol.14, issue.4, pp.41-59, 2014.
DOI : 10.1186/1479-5876-11-28

A. Zandvliet, J. Schellens, J. Beijnen, and A. Huitema, Population Pharmacokinetics and Pharmacodynamics for Treatment Optimization??in Clinical Oncology, Clinical Pharmacokinetics, vol.63, issue.8, pp.487-513, 2008.
DOI : 10.1038/clpt.1992.97

C. Meille, D. Barbolosi, J. Ciccolini, G. Freyer, and A. Iliadis, Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy, Clinical Pharmacokinetics, vol.4, issue.5, pp.1015-1040, 2016.
DOI : 10.2147/TCRM.S3397

H. Skipper, F. Schabel, J. Wilcox, and W. , Experimental Evaluation of Potential Anticancer Agents. Xiii. On the Criteria and Kinetics Associated with " Curability " of Experimental Leukemia, Cancer Chemother Rep, vol.35, pp.1-111, 1964.

L. Norton and R. Simon, Tumor size, sensitivity to therapy, and design of treatment schedules, Cancer Treat Rep, vol.61, pp.1307-1324, 1977.

M. Simeoni, P. Magni, C. Cammia, D. Nicolao, G. Croci et al., Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents, Cancer Research, vol.64, issue.3, pp.1094-101, 2004.
DOI : 10.1158/0008-5472.CAN-03-2524

M. Simeoni, D. Nicolao, G. Magni, P. Rocchetti, M. Poggesi et al., Modeling of human tumor xenografts and dose rationale in oncology, Drug Discovery Today: Technologies, vol.10, issue.3, pp.365-72, 2013.
DOI : 10.1016/j.ddtec.2012.07.004

C. Faivre, E. Cheikh, R. Barbolosi, D. Barlesi, and F. , Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients, British Journal of Cancer, vol.24, issue.3
DOI : 10.1016/0169-5002(93)90307-J

S. Benzekry and P. Hahnfeldt, Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers, Journal of Theoretical Biology, vol.335, pp.235-279, 2013.
DOI : 10.1016/j.jtbi.2013.06.036
URL : https://hal.archives-ouvertes.fr/hal-00836032

G. Karagiannis, J. Pastoriza, Y. Wang, A. Harney, D. Entenberg et al., Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism, Science Translational Medicine, vol.6, issue.397, 2017.
DOI : 10.1038/srep36142
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592784/pdf

M. Kioi, H. Vogel, G. Schultz, R. Hoffman, G. Harsh et al., Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice, Journal of Clinical Investigation, vol.120, issue.3, pp.694-705, 2010.
DOI : 10.1172/JCI40283DS1

G. Ahn, D. Tseng, C. Liao, M. Dorie, A. Czechowicz et al., Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment, Proceedings of the National Academy of Sciences, vol.116, issue.10, pp.8363-8371, 2010.
DOI : 10.1172/JCI24612

M. Timaner, R. Bril, O. Kaidar-person, C. Rachman-tzemah, D. Alishekevitz et al., Dequalinium blocks macrophage-induced metastasis following local radiation, Oncotarget, vol.6, issue.29, pp.27537-54, 2015.
DOI : 10.18632/oncotarget.4826
URL : http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=4826&path%5B%5D=11893

A. Bono, P. Bianchi, A. Locatelli, A. Calleri, J. Quarna et al., Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs open surgery for colorectal cancer, Cancer Biology & Therapy, vol.10, issue.7, pp.682-687, 2010.
DOI : 10.4161/cbt.10.7.12898

R. Leonard, B. Hennessy, J. Blum, O. Shaughnessy, and J. , Dose-Adjusting Capecitabine Minimizes Adverse Effects While Maintaining Efficacy: A Retrospective Review of Capecitabine for Metastatic Breast Cancer, Clinical Breast Cancer, vol.11, issue.6, pp.349-56, 2011.
DOI : 10.1016/j.clbc.2011.06.005

W. Evans, M. Relling, J. Rodman, W. Crom, J. Boyett et al., Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia, New England Journal of Medicine, vol.338, issue.8, pp.499-505, 1998.
DOI : 10.1056/NEJM199802193380803

G. Bocci and R. Kerbel, Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect, Nature Reviews Clinical Oncology, vol.33, issue.11, pp.659-73, 2016.
DOI : 10.1038/clpt.2014.153

L. Minasian, O. Rosen, D. Auclair, A. Rahman, R. Pazdur et al., Optimizing Dosing of Oncology Drugs, Clinical Pharmacology & Therapeutics, vol.310, issue.5, pp.572-581, 2014.
DOI : 10.1001/jama.2013.7900

Y. Shaked, T. Tang, J. Woloszynek, L. Daenen, S. Man et al., Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents, Cancer Research, vol.69, issue.19, pp.7524-7532, 2009.
DOI : 10.1158/0008-5472.CAN-09-0381

M. Egeblad and Z. Werb, New functions for the matrix metalloproteinases in cancer progression, Nature Reviews Cancer, vol.78, issue.3, pp.161-74, 2002.
DOI : 10.1002/(SICI)1097-0215(19981123)78:5<629::AID-IJC17>3.0.CO;2-8

Y. Shaked, F. Bertolini, S. Man, M. Rogers, D. Cervi et al., Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis, Cancer Cell, vol.7, issue.1, pp.101-112, 2005.
DOI : 10.1016/j.ccr.2004.11.023

N. Philpott, A. Turner, J. Scopes, M. Westby, J. Marsh et al., The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques, Blood, vol.87, pp.2244-51, 1996.

K. Burnham and D. R. Anderson, Model selection and multimodel inference: a practical information-theoretic approach, 2003.
DOI : 10.1007/b97636

P. Hoel, Introduction to Mathematical Statistics., Economica, vol.22, issue.86, 1962.
DOI : 10.2307/2626867